WST Stock West Pharmaceutical Services (WST, $330.05) Moving Average Convergence Divergence (MACD) Histogram turned positive on December 13, 2024

GET DAILY SIGNALS

Get AI intraday signals

WST - West Pharmaceutical Services

MACD signal

View

Odds of UP Trend

Price: $330.05

Daily change: -$1.57 (-0.47%)

Daily volume: 516.1K

Capitalization: $23.9B

Industry: Medical Specialties

WST in +1.87% Uptrend, rising for three consecutive days on December 20, 2024

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where WST advanced for three days, in of 339 cases, the price rose further within the following month. The odds of a continued upward trend are .

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 12, 2024. You may want to consider a long position or call options on WST as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for WST just turned positive on December 13, 2024. Looking at past instances where WST's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

WST moved above its 50-day moving average on November 20, 2024 date and that indicates a change from a downward trend to an upward trend.

Bearish Trend Analysis

The 10-day RSI Indicator for WST moved out of overbought territory on November 14, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 58 cases where WST's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where WST declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

WST broke above its upper Bollinger Band on December 12, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. WST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.060) is normal, around the industry mean (23.350). P/E Ratio (50.246) is within average values for comparable stocks, (83.485). Projected Growth (PEG Ratio) (7.006) is also within normal values, averaging (5.667). Dividend Yield (0.002) settles around the average of (0.018) among similar stocks. P/S Ratio (10.111) is also within normal values, averaging (43.451).